Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Protara Therapeutics Inc. TARA

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).


Recent & Breaking News (NDAQ:TARA)

Mid-Day Market Update: U.S. Stocks Turn Lower; Quantenna Communications Shares Surge

Benzinga.com  March 28, 2019

Proteon Therapeutics Announces Publication of Results from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with Chronic Kidney Disease

GlobeNewswire January 24, 2019

New Research Coverage Highlights Yum! Brands, TELUS, Unifi, Proteon Therapeutics, Sabine Royalty Trust, and Algonquin Power & Utilities — Consolidated Revenues, Company Growth, and Expectations for 2018

GlobeNewswire November 16, 2018

Proteon Therapeutics to Present at the Stifel 2018 Healthcare Conference November 13th

GlobeNewswire November 8, 2018

Proteon Therapeutics Announces Third Quarter 2018 Financial Results

GlobeNewswire November 7, 2018

Proteon Therapeutics to Present at Two Upcoming Investor Conferences

GlobeNewswire August 29, 2018

Proteon Therapeutics Announces Second Quarter 2018 Financial Results

GlobeNewswire August 7, 2018

Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 21st

GlobeNewswire June 14, 2018

Proteon Therapeutics Announces First Quarter 2018 Financial Results

GlobeNewswire May 9, 2018

Proteon Therapeutics and Lonza Extend Manufacturing Agreement for Commercial Supply

GlobeNewswire May 8, 2018

Proteon Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results

GlobeNewswire March 14, 2018

Proteon Therapeutics to Present at Two Upcoming Investor Conferences

GlobeNewswire March 6, 2018

Proteon Therapeutics Completes Enrollment in PATENCY-2, Phase 3 Clinical Trial of Investigational Vonapanitase

GlobeNewswire March 5, 2018

Proteon Therapeutics to Present at the Stifel 2017 Healthcare Conference November 15th

GlobeNewswire November 8, 2017

Proteon Therapeutics Announces Third Quarter 2017 Financial Results

GlobeNewswire November 7, 2017

Proteon Therapeutics to Present at the Baird 2017 Global Healthcare Conference September 7, 2017

GlobeNewswire September 5, 2017

Proteon Therapeutics Announces Second Quarter 2017 Financial Results

GlobeNewswire August 7, 2017

Proteon Therapeutics Announces Closing of $22 Million Convertible Preferred Stock Financing

GlobeNewswire August 2, 2017

Proteon Therapeutics Announces $22.0 Million Private Placement

GlobeNewswire June 22, 2017

Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 21st

GlobeNewswire June 15, 2017